Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...

Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...

Drugmaker Boehringer Ingelheim and prescription savings platform GoodRx have teamed up to provide Boehringer’s Humira biosimilar for an exclusive cash price on GoodRx, the companies announced Thursday ...

In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. In a new effort to crack the popular immunology drug’s 82% grasp on the market ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...

UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...

Adalimumab, sold under the brand name Humira, enjoyed a long run as one of the world's best-selling medicines. But its 20-year, competition-free period has ended, and despite its best efforts to delay ...

A year ago, Blue Shield of California announced that it would move on from a traditional pharmacy benefit management relationship with CVS' Caremark and instead adopt a new model that leans on ...

Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the originator's ...